Navigation Links
Sanford-Burnham Medical Research Institute and Mayo Clinic extend collaborative agreement
Date:3/11/2013

LA JOLLA, Calif., March 11, 2013 Sanford-Burnham Medical Research Institute (Sanford-Burnham) and Mayo Clinic signed a new collaborative agreement to build a pipeline of therapeutic drugs aimed at a variety of diseases with serious unmet medical needs. Under this agreement, Mayo Clinic scientists will work with researchers in Sanford-Burnham's Conrad Prebys Center for Chemical Genomics (Prebys Center) to conduct early-stage drug discovery, including assay development, high-throughput screening, and lead identification. Sanford-Burnham, an independent research institute, is recognized for establishing novel collaborations with clinical organizations to expedite early-phase drug discovery.

The agreement combines Mayo Clinic's clinically relevant targets with Sanford-Burnham's discovery platform in a translational initiative aimed at advancing a portfolio of projects through the initial stages of drug discovery. The new agreement builds on a yearlong pilot phase and expands the number and scope of drug discovery projects derived from Mayo Clinic researchers that are being conducted at Sanford-Burnham.

"We're looking forward to further engaging with our Mayo Clinic collaborators as we develop innovative screens to identify chemical compounds that modulate the activity of clinically relevant targets," said Michael Jackson, Ph.D., vice president of drug discovery and development at Sanford-Burnham. "If successful, these compounds will form the basis of completely novel'first in class'therapies for devastating diseases such as cancer, Alzheimer's, and others."

In Sanford-Burnham's Prebys Center, Jackson and a team of researchersmany of them recruited from the pharmaceutical industryuse state-of-the-art, ultra-high throughput screening systems to sift through the Institute's compound library, recognized as one of the largest collections in the nonprofit research community.

"The Mayo Clinic-Sanford-Burnham collaboration provides an avenue for Mayo scientists to rapidly translate basic science discoveries into screening platforms that will enable new drug discovery, and a new paradigm in drug development," said Andrew Badley, M.D., associate dean of research resources at Mayo Clinic.

Kristiina Vuori, M.D., Ph.D., Sanford-Burnham's president and interim CEO, agreed, adding that "this collaborative model provides interactions between researchers with deep expertise in drug discovery technologies, basic research scientists and clinical scientists that will expedite the drug discovery process and offer a clinical outlet for testing potential new drugs."


'/>"/>
Contact: Heather Buschman
hbuschman@sanfordburnham.org
858-795-5343
Sanford-Burnham Medical Research Institute
Source:Eurekalert  

Related biology news :

1. Sanford-Burnham and 60° Pharmaceuticals to pursue promising target for the treatment of dengue fever
2. Sanford-Burnham and Intrexon Corporation establish collaboration to accelerate stem cell research
3. NIH New Innovator Award helps Sanford-Burnham scientist pursue high-risk, high-reward project
4. Californias stem cell agency boosts heart disease research at Sanford-Burnham
5. Promiscuous enzymes may be recruited to aid industry, medical fields
6. WPI Biomedical Technology in final 4 of international business plan contest
7. 3 Johns Hopkins researchers recognized for medical inventions
8. Breakthrough study opens door to broader biomedical applications for Raman spectroscopy
9. Medbox Partners with Bio-Tech Medical Software to Create Nations Safest Prescription Drug and Medical Marijuana Distribution System
10. Sex and gender competency essential to medical care
11. Hastings Center resources chart progress in debate over medical research with animals
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sanford-Burnham Medical Research Institute and Mayo Clinic  extend collaborative agreement
(Date:12/22/2016)... VIEW, Calif. , Dec. 20, 2016  As part ... levels, 23andMe, the leading personal genetics company, recently released its ... Me . The book focuses on the topics of ... Next Generation Science Standards (NGSS) taught in elementary school classrooms ... second in a series by illustrator Ariana Killoran , ...
(Date:12/19/2016)... , España y TORONTO , 19 de ... con Northern Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, ... clínicos en varios tipos de tumor en 2017, con múltiples sitios ... ... su clase con objetivo en el factor inhibidor de leucemia (LIF), ...
(Date:12/15/2016)... and BADEN-BADEN, Germany , December 15, ... global financial services provider, today announced an agreement with NuData ... biometrics, to join forces. The partnership will enable clients to ... in compliance with local data protection regulation. ... In order to provide ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... ... January 17, 2017 , ... Pono Ola , a mind-body ... lifestyle, announced today the official launch of its much-anticipated Pono Board: a re-invented fitness ... , In development for over a year, the patented Pono Board is the world’s ...
(Date:1/17/2017)... Ohio , Jan. 17, 2017  On January ... the 35th Annual J.P. Morgan Healthcare Conference in ... Joseph D. Kittle, Jr. , spoke to pharmaceutical leaders ... developed by ProclaRx to break down and destroy biofilms.  ... protect bacteria and prevent antibiotics and the body,s immune ...
(Date:1/14/2017)... CA (PRWEB) , ... January 14, 2017 , ... ... Proximo™, a new service providing complete end-to-end genome assemblies to researchers around the ... genomes eliminates a major obstacle in answering a wide range of scientific questions. ...
(Date:1/13/2017)... ... January 13, 2017 , ... FireflySci has been busy ... among its diverse customer base. The latest entry in this field is a ... BTX and Bio-Rad. FireflySci is introducing three distinct varieties including a 10x1mm, 10x2 ...
Breaking Biology Technology: